scholarly journals Membrane Fixation of Vascular Endothelial Growth Factor Receptor 1 Ligand-Binding Domain Is Important for Vasculogenesis and Angiogenesis in Mice

2005 ◽  
Vol 25 (1) ◽  
pp. 346-354 ◽  
Author(s):  
Sachie Hiratsuka ◽  
Kazuki Nakao ◽  
Kenji Nakamura ◽  
Motoya Katsuki ◽  
Yoshiro Maru ◽  
...  

ABSTRACT Vascular endothelial growth factor (VEGF) regulates vasculogenesis and angiogenesis by using two tyrosine kinase receptors, VEGFR1 and VEGFR2. VEGFR1 null mutant mice die on embryonic day 8.5 (E8.5) to E9.0 due to an overgrowth of endothelial cells and vascular disorganization, suggesting that VEGFR1 plays a negative role in angiogenesis. We previously showed that the tyrosine kinase (TK) domain of VEGFR1 is dispensable for embryogenesis, since VEGFR1 TK-deficient mice survived and were basically healthy. However, the molecular basis for this is not yet clearly understood. To test the hypothesis that the specific role of VEGFR1 during early embryogenesis is to recruit its ligand to the cell membrane, we deleted the transmembrane (TM) domain in TK-deficient VEGFR1 mice. Surprisingly, about half of the VEGFR1(TM-TK)-deficient mice succumbed to embryonic lethality due to a poor development of blood vessels, whereas other mice were healthy. In VEGFR1(TM-TK)−/− mice with growth arrest, membrane-targeted VEGF was reduced, resulting in the suppression of VEGFR2 phosphorylation. Furthermore, the embryonic lethality in VEGFR1(TM-TK)−/− mice was significantly increased to 80 to 90% when the genotype of VEGFR2 was changed from homozygous (+/+) to heterozygous (+/−) in 129/C57BL6 mice. These results strongly suggest that the membrane-fixed ligand-binding region of VEGFR1 traps VEGF for the appropriate regulation of VEGF signaling in vascular endothelial cells during early embryogenesis.

Blood ◽  
2005 ◽  
Vol 105 (5) ◽  
pp. 1970-1976 ◽  
Author(s):  
Margherita Gallicchio ◽  
Stefania Mitola ◽  
Donatella Valdembri ◽  
Roberto Fantozzi ◽  
Brian Varnum ◽  
...  

AbstractGAS6, the product of a growth arrest specific (GAS) gene, is the ligand of the tyrosine kinase receptor Axl. GAS6 and Axl are both expressed in endothelial cells, where they are involved in many processes such as leukocyte transmigration through capillaries and neointima formation in injured vessels. Here, we show that Axl stimulation by GAS6 results in inhibition of the ligand-dependent activation of vascular endothelial growth factor (VEGF) receptor 2 and the consequent activation of an angiogenic program in vascular endothelial cells. GAS6 inhibits chemotaxis of endothelial cells stimulated by VEGF-A isoforms, but not that triggered by fibroblast growth factor-2 or hepatocyte growth factor. Furthermore, it inhibits endothelial cell morphogenesis on Matrigel and VEGF-A–dependent vascularization of chick chorion allantoid membrane. GAS6 activates the tyrosine phosphatase SHP-2 (SH2 domain-containing tyrosine phosphatase 2), which is instrumental in the negative feedback exerted by Axl on VEGF-A activities. A dominant-negative SHP-2 mutant, in which Cys 459 is substituted by Ser, reverted the effect of GAS6 on stimulation of VEGF receptor 2 and endothelial chemotaxis triggered by VEGF-A. These studies provide the first demonstration of a cross talk between Axl and VEGF receptor 2 and add new information on the regulation of VEGF-A activities during tissue vascularization.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2575-2575
Author(s):  
Gexiu Liu ◽  
Dongmei He ◽  
Yanhui Wu

Abstract INTRODUCTION: High level of vascular endothelial growth factor (VEGF) and stromal-derived factor (SDF-1) are often expressed in many carcinoma tissues that are accompanied by intense neovascularization. VEGF is a key regulator of blood vessel formation during both vasculogenesis and angiogenesis. Mesenchymal stem cells (MSCs) in peripheral blood that are released from the bone marrow can be strongly attracted by SDF-1. Low oxygen tension is thought to be an integral component of the tumor microenvironment. To examine tumor angiogenesis in the tumor microenvironment, we studied that SDF-1 and VEGF both can induce MSCs to differentiate into endothelial cells (ECs) in hypoxia condition. METHODS: Adult Sprague-Dawley rat bone marrow MSCs were purified and maintained in DMEM/F12 containing 10% FBS, and were characterized by high expression of CD44, the lack of CD45 and CD11b molecules, their typical spindle-shaped morphology, together with their ability to differentiate into osteogenic, chondrogenic, and adipogenic cells. Subconfluent MSCs were used, were maintained with DMEM/F12 containing 10% FBS in hypoxia condition (93% N2 + 2% O2 +5% CO2), and were treated with or without VEGF and/or SDF-1. During induction, cell morphology, the vascular endothelial markers VE-cadherin and von Willebrand factor (vWF), and mesenchymal cell marker CD44 were observed. After induction, functions of cells were examined. RESULTS: MSCs treated with both VEGF and SDF-1 for 7 days in hypoxic condition changed morphologically and adopted a caudate appearance with rod-shaped microtubulated structures resembling Weibel-Palade bodies, and formed mature endothelial cell tubules in Matrigel(R) cultures after 15 days. Almost every cell expressed VE-cadherin and vWF [(98.32±1.39)%], but CD44 expression was markedly down-regulated. Functional characteristics of vWF release upon histamine stimulation in response to hypoxia were indistinguishable between the MSC-derived endothelial-like cells and cultured mature ECs. The best condition for the differentiation was the combination of 0.3 nM VEGF and 100 ng/ml SDF-1 at a culture duration of 10 to 15 days. However, the positive ratio of both VE-cadherin and vWF in cells induced by different concentration of SDF-1 alone or VEGF alone was lower [(8.35±2.89)% and (27.33±3.26)%, respectively]. The positive ratio of both VE-cadherin and vWF in cells induced by the best combination of 0.3 nM VEGF and 100 ng/ml SDF-1 in normoxic culture condition was (34.91±3.47)%. Finally, in xenogenic transplantation studies using a SCID mouse model, non-small cell lung cancer cells were injected subcutaneously with the MSC-derived endothelial-like cells induced by the best condition. As a result, co-transplantation of the cells promoted the formation of blood vessels. Immunohistochemistry and FISH analysis showed that the MSC-derived cells incorporated tumor vasculogenesis and angiogenesis. CONCLUSION: Stromal-derived factor and vascular endothelial growth factor synergistically induce bone marrow-derived mesenchymal stem cells to differentiate into endothelial cells in hypoxia condition, which incorporated tumor vasculogenesis and angiogenesis. These results suggest that targeting MSCs-derived angiogenesis might be a novel efficient antiangiogenesis strategy to treat cancer.


2001 ◽  
Vol 21 (14) ◽  
pp. 4647-4655 ◽  
Author(s):  
Iiro Rajantie ◽  
Niklas Ekman ◽  
Kristiina Iljin ◽  
Elena Arighi ◽  
Yuji Gunji ◽  
...  

ABSTRACT The Bmx gene, a member of the Tec tyrosine kinase gene family, is known to be expressed in subsets of hematopoietic and endothelial cells. In this study, mice were generated in which the first coding exon of the Bmx gene was replaced with thelacZ reporter gene by a knock-in strategy. The homozygous mice lacking Bmx activity were fertile and had a normal life span without an obvious phenotype. Staining of their tissues using β-galactosidase substrate to assess the sites ofBmx expression revealed strong signals in the endothelial cells of large arteries and in the endocardium starting between days 10.5 and 12.5 of embryogenesis and continuing in adult mice, while the venular endothelium showed a weak signal only in the superior and inferior venae cavae. Of the five known endothelial receptor tyrosine kinases tested, activated Tie-2 induced tyrosyl phosphorylation of the Bmx protein and both Tie-2 and vascular endothelial growth factor receptor 1 (VEGFR-1) stimulated Bmx tyrosine kinase activity. Thus, the Bmx tyrosine kinase has a redundant role in arterial endothelial signal transduction downstream of the Tie-2 and VEGFR-1 growth factor receptors.


2001 ◽  
Vol 280 (2) ◽  
pp. H885-H891 ◽  
Author(s):  
Outi Saijonmaa ◽  
Tuulikki Nyman ◽  
Riikka Kosonen ◽  
Frej Fyhrquist

The role of vascular endothelial growth factor (VEGF), a potent endothelium-specific angiogenic factor, in the regulation of angiotensin-converting enzyme (ACE) in cultured human umbilical vein endothelial cells (HUVECs) was studied. VEGF (0.07–1.2 × 10−6mmol/l) caused a dose-dependent increase in ACE measured in intact endothelial cells and increased the expression of ACE mRNA. The stimulatory effect of VEGF was inhibited by pretreatment of endothelial cells with the tyrosine kinase inhibitor herbimycin (4.35 × 10−5mmol/l). The stimulatory effect of VEGF was potentiated by the selective cGMP phosphodiesterase inhibitor zaprinast (0.1 mmol/l). The nitric oxide synthase inhibitor Nω-nitro-l-arginine methyl ester (l-NAME; 5.4 mmol/l) suppressed the stimulatory effect of VEGF. The nonselective cyclooxygenase (COX) inhibitor indomethacin (5 μM) and the selective COX-2 inhibitor NS-398 (5 μM) potentiated the stimulatory effect of VEGF, whereas the selective COX-1 inhibitor resveratrol (5 μM) was without effect. ACE induction by VEGF was inhibited by the selective protein kinase C (PKC) inhibitor GF109203X (2.5 × 10−3mmol/l) and by downregulating PKC with phorbol 12-myristate 13-acetate. In summary, VEGF induced ACE in cultured HUVECs. Intracellular events such as tyrosine kinase activation, PKC activation, and increase of cGMP were probably involved in ACE induction by VEGF. Nitric oxide may partially contribute to ACE induction by VEGF. The powerful capacity of VEGF to increase ACE in endothelial cells shown here suggests a synergistic relation between VEGF and the renin-angiotensin system in vascular biology and pathophysiology.


Sign in / Sign up

Export Citation Format

Share Document